Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction

Ugo Corrà¹, Alessandra Magini², Stefania Paolillo³ and Maria Frigerio⁴

Abstract
Heart failure is a serious condition with high prevalence (about 2% in the adult population in developed countries, and more than 8% in patients older than 75 years). About 3–5% of hospital admissions are linked with heart failure incidents. The guidelines of the European Society of Cardiology for the diagnosis and treatment of acute and chronic heart failure have identified individual markers in patients with heart failure, including demographic data, aetiology, comorbidities, clinical, radiological, haemodynamic, echocardiographic and biochemical parameters. Several scoring systems have been proposed to identify adverse events, such as destabilizations, re-hospitalizations and mortality. This article reviews scoring systems for heart failure prognostication, with particular mention of those models with exercise tolerance objective definition. Although most of the models include readily available clinical information, quite a few of them comprise circulating levels of natriuretic peptides and a more objective evaluation of exercise tolerance. A literature review was also conducted to (a) identify heart failure risk-prediction models, (b) assess statistical approach, and (c) identify common variables.

Keywords
Risk prediction models, heart failure

Received 11 July 2020; accepted 8 September 2020

Few topics have received as much attention in medical literature over recent years as risk prediction in heart failure patients, especially in those with reduced ejection fraction (HFrEF). Estimation of prognosis in HFrEF is crucial¹ for patients who are concerned about the probability of future events, for families who are worried about obligations, aspirations, fears, limitations, resources, and needs of relatives, and for physicians who like to decide the type and timing of additional tests or therapies with reliable and objective criteria.²³

A proper prognostic risk model for HFrEF
In theory, a multiparametric prognostic model should be as good as the variables from which it is derived. However, the relevance of individual prognostic markers may vary according to the phase of the disease and the presence and value of accompanying variables — including non-cardiac comorbidities. Basic demographic and clinical variables such as age, gender, aetiology of disease and history of hospitalizations have a

¹Cardiac Rehabilitation Division, IRCCS Istituti Clinici Scientifici Maugeri Spa SB, Italy
²Centro Cardiologico Monzino IRCCS, Italy
³Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy
⁴DeGasperis CardioCenter, Niguarda Hospital, Italy

Corresponding author:
Ugo Corrà, Cardiac Rehabilitation Division, IRCCS Istituti Clinici Scientifici Maugeri Spa SB, Italy.
Email: ugo.corra@icsmaugeri.it
prognostics role. Their predictive value declines as heart failure becomes progressively more severe, and left ventricular ejection fraction (LVEF) also declines, although in several experiences female sex appears to be protective even in advanced stages of disease. In the general population, increased systolic blood pressure (SBP) and body mass index (BMI) are associated with worse outcomes; however, once HFrEF has developed, a reverse epidemiology is observed, and higher SBP and BMI are associated with lower risk. For example, a 10% reduction in mortality for each five-unit increase in BMI was seen in a large registry of acutely decompensated HFrEF. Impaired socioeconomic status has been shown to be a predictor of poor outcome, whereas the impact of race on mortality is controversial: some studies showed increased rates of hospitalization, while others exhibited a survival advantage in Black HFrEF patients.

Many univariate predictors, such as clinical features, New York Heart Association (NYHA) functional class, haemodynamic parameters, laboratory findings, several biomarkers, electrocardiographic and echocardiographic parameters, cardiac magnetic resonance imaging and coronary angiographic findings, have been shown to correlate with prognosis. Some findings at physical examination (e.g. third heart sound, increased jugular venous pressure) are associated with lower probability of survival, but their reproducibility is low since they are influenced by subjective appreciation. NYHA classification is also related to survival in HFrEF, but it depends also on subjective appreciation of symptoms by the patients. Several laboratory markers have revealed an independent association with prognosis. B-type natriuretic peptides (BNPs) have received most of the attention in recent years. The quartile of patients with the lowest N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the placebo arm of the Valsartan Heart Failure Trial (Val-HeFT) had less than one-third the mortality (7.8%) of patients in the highest quartile (25.3%). NT-proBNP level at baseline and at discharge entered as independent markers of the risk of death in hospital and during follow-up, respectively, in a multicentre cohort of patients hospitalized for decompensated, advanced HFrEF. Many echocardiographic parameters of both right and left ventricular function show correlation with prognosis, of which LVEF is the most popular and probably the most relevant. Lower LVEF was associated with worse outcome in the CHARM programme: 1013 patients with an ejection fraction <23% had triple the all-cause mortality and quadruple the heart failure progression-related mortality of the 2795 patients with an ejection fraction >42%. When LVEF is severely reduced in all the patients, indexes of right ventricular function may help in further risk stratification.

In HFrEF, oxygen consumption at peak exercise (peak VO2) includes two relevant aspects related to impaired physiologic processes: cardiac output and the ability to extract oxygen from circulating blood. Peak VO2 has been used for selection of heart transplant candidates for years; excessive ventilatory response to exercise (measured as an elevated slope of ventilation per unit of carbon dioxide production (VE/VCO2 slope)) is a powerful risk predictor, perhaps secondary to abnormal cardiopulmonary reflexes; VE/VCO2 slope >34–36 identifies high risk patients, beyond peak VO2. Thus, symptom-limited CPET relies on different gas exchange parameters that have, as individual factors, a prognostic impact.

Other variables that frequently resulted to have high predictive value in multiparametric scores were blood urea nitrogen and sodium. Cancer, acidosis expressed by arterial pH or blood lactate, and renal failure were highly predictive in case–control studies, but not in prognostic cohort studies. The opposite was seen with ejection fraction and BNPs, which were found to be highly prognostic in cohort studies but not in case–control studies. In the advanced heart failure models, the strongest predictor variable was heart failure admissions.

Beside characteristics of patients’ clinical presentation, interventions have an impact on prognosis. HFrEF treatments significantly reduce mortality, and their effects on survival must be included in any discussion of prognosis. In the absence of evidence-based therapies, whatever the cause, patients become more critically ill. Being aware of the effects of therapies on the predicted mortality according to the Seattle Heart Failure Model (SHFM) led to an escalation of pharmaceutical or device-based therapy for 82% of observed patients. Implanted cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) are devices that may alter the outcome and course of the disease: ICD shows a 25–30% relative reduction in all-cause mortality in patients with myocardial infarction and reduced ejection fraction while in patients with wide QRS and left bundle branch block morphology CRT improves symptoms and survival.

Therapeutic options for refractory HFrEF are heart transplantation (HTx), left ventricular assist device (LVAD) and continuous intravenous inotropes. The average post-transplant survival is about 10–15 years, while destination therapy LVADs is followed by 5–10 years of survival in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. Various models have been proposed for assessment of outcomes after
LVAD placement. The INTERMACS classification describes patient pre-implant conditions. The INTERMACS 1 and 2 compared with 3 and 4 profiles demonstrated statistically significant 44% versus 11% mortality within 30 days after VAD placement, but later on INTERMACS 1 and 2 patients actually showed lower mortality than the 3 and 4 patients when considering only 30-day survivors.35 A comparison of the INTERMACS, Destination Therapy Risk Score, Acute Physiology and Chronic Health Evaluation II, SHFM and Columbia risk scores in patients receiving a LVAD showed the SHFM risk score to have the strongest association with mortality.36 Treatment with positive inotropic medications has an unquestionably deleterious effect:37 HFrEF patients dependent on continuous home dobutamine show a median survival as low as little months and a six-month mortality of 50%. Thus, long-term inotropes can be used cautiously only as a symptomatic therapy when other options are precluded.

In summary, allocating patients to one strategy or another is highly dependent on underlying survival expectation. As clinical practice guidelines continue to move toward personalized treatment recommendations that are tailored to the unique benefit–harm assessments of a given patient, integration of clinical risk prediction equations will remain essential for guiding absolute risk assessment. Predicting the future is an imperfect science: quantitative risk assessment is just the start, not the end, of a treatment decision. Risk estimates must be contextualized by clinicians.38,39 Table 1 summarizes the multidimensional risk stratification in HFrEF.

Table 1. Acknowledged risk aspects in heart failure due to left ventricular systolic dysfunction.

| Demographic data | Age, male, low socioeconomic status |
|------------------|-----------------------------------|
| Severity of heart failure Clinical status | NYHA class, duration of HFrEF, peak VO₂, VE/VCO₂ slope, distance at 6mWT |
| Myocardial and LV dysfunction severity | LVEF, LV systolic and diastolic chamber size, filling pressure, LV hypertrophy, valvular disease (mitral regurgitation, aortic stenosis), RV and LA dimension, pulmonary pressure, dysynchrony, area of hypo/akinesia, wide QRS complex, presumed infiltration or inflammatory, inducible ischaemia, poor viability |
| Biomarkers | Sodium, natriuretic peptide, plasma renin activity, aldosterone and catecholamines, endothelin-I, vasopressin, renal function, inflammatory, cardiac stress, cardiac damage markers, Metabolic and collagen and organ dysfunction markers |
| Cardiovascular co-morbidities | Diabetes, anaemia, atrial fibrillation, renal and hepatic dysfunction, COPD, depression, dementia, sleep apnoea |
| Non-adherence Events | With recommended HFrEF treatment HFrEF hospitalization, aborted cardiac arrest, ICD shock |

Factors limiting the use in clinical practice of risk models

Why are risk models not used in clinical assessment? One major cause is the type of outcome. Risk models that are designed to predict the combined outcome of death or hospitalization, or of hospitalization only, had a poorer discriminative ability than those designed to predict cardiac or all-cause death. This may happen because differences in the probability of hospitalization are more difficult to foresee, and hospitalizations depend also on healthcare delivery organization;40 therefore, non-fatal events are rarely included in risk score. Moreover, risk scores generally do not predict the mode of death and do not account for the associated changes in quality of life.3 Risk models for prognostication in advanced heart failure, for example, the Heart Failure Survival Score (HFSS) and the Metabolic Exercise Cardiac Kidney Index (MECKI) score, often refer to the combined outcome of death or HTx, and/or LVAD implant. This is motivated by the fact that both HTx and LVAD may be considered life-saving therapies that have the potential to change radically the destiny of these patients, especially when performed in an acute, emergency condition (‘urgent’ HTx, or LVAD with INTERMACS profile 1–3). However, performing HTx and LVAD depends not only on patients’ medical characteristics, but also on individual choices (by the patient and by the medical staff), on non-medical characteristics (e.g. blood type 0 and large size reduce the probability of getting a HTx), and on events that may be considered causal (again, availability of a suitable donor) but in fact are also influenced by organization of healthcare (e.g. policy
for donor retrieval and allocation), and they vary widely from country to country.

Another source of heterogeneity is the clinical presentation of HFrEF patients: risk in chronic/acute, advanced/moderate HFrEF is different, and improvements have been seen between both inpatients and outpatients.3

Moreover, like most statistical analyses, risk scores perform well for large groups of individuals and for the intermediate term, but they perform very poorly for individuals and for the short term.3 A further complicating issue is the time horizon of risk scores, which may span from one to five years (the time horizon varied considerably among the studies identified, with few studies providing sufficient information to confirm robustness and generalizability to qualify the prognosis of individual patients), which may not be an adequate time frame in which to make lifestyle decisions, particularly in younger, less severely affected patients.3

Such a complex interplay cannot be reduced to the binary outcome of alive or dead.

**Statistical techniques**

Generation of a risk model requires to get access to a robust dataset and to apply several statistical techniques.29,39,40 Starting with a set of univariate predictors and applying a Cox proportional hazards model or logistic regression are the most used techniques (if patient follow-up is not uniform, a Cox-based analysis is the best statistical technique, while logistic regression analysis is most appropriate when follow-up is completed). Significant risk variables can be transformed by an equation into a continuous number, or one or more points may be attributed to individual significant factors, which are summed up to build the final score. Thresholds for defining low, intermediate and high-risk categories may be identified. Validation consists of analysis of the C statistic or area under the receiver-operator characteristic curve (AUC): assessment of the sensitivity and specificity of the predictive model.

The additional value of new proposed markers may be evaluated with several statistical approaches – such as the net reclassification and integrated discrimination improvement.1 Moreover, to integrate risk prediction models into the decisional process and the healthcare management must be carried out keeping an eye on possible biases and on how missing data have been handled. In a review,39 only 28% of the studies reported on how they handled missing data. This highlights the need for a significant improvement in the quality of data reporting.

Machine learning methods based on administrative claims offered limited improvement over logistic regression in predicting outcomes.40 Inclusion of additional clinical parameters from electronic medical records improved prediction for some outcomes. Models derived with reference to administrative data may be helpful in identifying high-risk target populations for deploying population-based interventions.

**Comparison among risk models (with the adjunction of cardiopulmonary exercise testing variables)**

The Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION)41 was a multicentre randomized controlled trial that tested the long-term safety and efficacy of aerobic exercise training plus evidence-based medical therapy versus evidence-based medical therapy alone in medically stable outpatients. The relationship between baseline clinical factors and the composite end point of death or all-cause hospitalization41 showed that exercise duration at the baseline cardiopulmonary exercise testing (CPET) was the most important predictor, while supplementary predictors were Kansas City Cardiomyopathy Questionnaire symptom stability score, serum urea nitrogen and male sex.42

Several risk models for HFrEF mortality have been developed,2 showing variable levels of success, and many of these models were developed and validated in selective cohorts of patients from clinical trials and may or may not perform in the same way in the so-called ‘real-world’ patients. Considering the aging of the population and the heterogeneity in clinical presentation and disease progression over time, a multiparametric approach is actually advocated as the best available strategy to predict HFrEF outcome. Because women are less represented in most clinical trials than men, risk models derived without validation in sex-specific cohorts may not have the same predictive accuracy as sex-specific heart failure risk models. A study was performed in 2225 advanced HFrEF patients; the 4 strongest predictors of outcome in both women and men were B-type natriuretic peptide, peak VO₂ by CPET, NYHA classification, and use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.43 In addition, the UCLA model performed better than the SHFM31 and the HFSS.44 A simple risk model assessing 4 clinical variables is well suited to provide prognostic information in HFrEF patients to verify whether the risk model was better with ejection fraction could be better in event-free survival.

In 2011, Goda et al. compared HFSS45 and SHFM in a large cohort of HFrEF patients which were under evaluation for HTx candidacy and had undergone CPET: the AUCs were similar.45 As the decision to
list ambulatory patients for HTx remains difficult, in 2012, Levy et al. appraised whether the addition of peak VO2 improved the predictive accuracy of the SHFM in 1240 patients; the outcomes were death/LVAD/urgent HTx, with patients being censored as alive at the time of elective transplant. The multivariate SHFM was a powerful predictor, and peak VO2 added prognostic information. Conversely, in 2015, Dardas et al. showed that integrating CPET variables or the 6-min walking distance with the SHFM improved only marginally the accuracy of risk predictions in 2152 ambulatory patients enrolled in HF-ACTION. Thus, CPET variables appear to be of particular relevance in the specific setting of advanced HFrEF.

The HFSS, SHFM and MECKI score were compared in a cohort of HFrEF patients that were able to perform symptom-limited CPET. The MECKI score exhibited a greater prognostic accuracy in terms of combination of cardiovascular death, urgent HTx and LVAD implantation: the superiority of the MECKI score was evident at two-year follow-up and was also confirmed at four years. The accompanying editorial stated that the MECKI model was judged in comparison with HFSS (peak VO2 and clinical data) and SHFM (no CPET data), and, as peak VO2 and VE/VCO2 are used by clinicians for the transplant listing, it was not too surprising that this risk model was superior to a clinical risk model. Freitas et al. compared the MECKI, SHFM, HFSS and MAGGIC risk models: all four models had a similar AUC for all-cause mortality at two years in 259 HFrEF patients. Therefore, a comparison between resting and exertional variables is in favour of the exercise ones in selected HFrEF cohorts and according to the outcome.

The MAGGIC risk model appeared to be more accurate than the CHARM and SHFM models in predicting one-year mortality at the population level; however, the reliability at the individual patient level was very poor. In a large number of chronic heart failure patients reported in the European Society of Cardiology Heart Failure Long-Term Registry, the MAGGIC risk model was more accurate. In a recent letter, MAGGIC and MECKI score were compared after cardiac rehabilitation in Holland; the MECKI score showed an excellent performance in Dutch HFrEF patients, and the MECKI score can appropriately monitor time-dependent changes in risk estimates for adverse outcomes in HFrEF.

Conclusions

Each risk model has its own peculiarities, depending on the overall aim of the study, target population, length of follow-up, health procedures assessed, location of study and accessibility to study data. Time horizon and sample size varied considerably among the studies identified, with few studies providing sufficient information to confirm robustness and generalizability to qualify the prognosis of individual patients. It is clear that there is a real need to integrate risk prediction models into healthcare management, but this must be carried out with an eye on bias and handling missing data. Comparing different risk models and accuracy of prognosis is a hard task. Most studies are exposed to criticisms relating to their construction.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Ketchum ES and Levy WC. Establishing prognosis in heart failure: A multimarker approach. Progr Cardiovasc Dis 2011; 54: 86–96.
2. Alba AC, Agoritsas T, Jankowski M, et al. Risk prediction models for mortality in ambulatory patients with heart failure. A systematic review. Circ Heart Fail 2013; 6: 881–889.
3. Howlett JG. Should we perform a heart failure risk score? Circ Heart Fail 2013; 6: 4–5.
4. Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439–1444.
5. Piepoli MF, Corrà U, Veglia F, et al.; on behalf of the MECKI Score Research Group. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: Data from the MECKI study group. Eur J Heart Fail 2016; 18: 545–553.
6. Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: Insights from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 116: 627–636.
7. Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: Analysis of body mass index and in hospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007; 153: 74–81.
8. Rector TS, Ringwala SN and Anand IS. Validation of a risk score for dying within 1 year of an admission for heart failure. J Card Fail 2006; 12: 276–280.
9. Girerd N, Seronde M-F, Coiro S, et al.; on behalf of INCRCT, Great Network, and the EF-HF Group. Integrative assessment of congestion in heart failure.
throughout the patient journey. JACC Heart Fail 2018; 6: 273–285.

10. Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454–2460.

11. Mozaffarian D, Nye R and Levy WC. Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933–1939.

12. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 2713–2723.

13. Horwich TB, Kalantar-Zadeh K, MacLellan RW, et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155: 883–889.

14. Van IJsebrrecht EH, Kim CH, Uithoven K, et al. Obesity and hemoglobin content impact peak oxygen uptake in human heart failure. Eur J Prev Cardiol 2018; 25: 1937–1946.

15. Bozkurt B, Mann DL and Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010; 15: 331–341.

16. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397.

17. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997–1003.

18. Scrutinio D, Ammirati E, Guida P, et al. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. Int J Cardiol 2013; 168: 2120–2126.

19. Scrutinio D, Passantino A, Guida P, et al. Incremental utility of prognostic variables at discharge for risk prediction in hospitalized patients with acutely decompensated chronic heart failure. Heart Lung 2016; 45: 212–219.

20. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183–188.

21. Badagliacca R, Ghio S, Correale M, et al. Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. Int J Cardiol 2018; 271: 301–305.

22. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738–3744.

23. Grayburn PA, Appleton CP, DeMaria AN, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: The Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2005; 45: 1064–1071.

24. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778–786.

25. Costanzo MR, Augustine S, Bourg R, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92: 3593–3612.

26. Gitt AK, Wasserman K, Kilkowski C, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation 2002; 106: 3079–3084.

27. Agostoni PG, Corrà U, Cattadori G, et al.; on behalf of the MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. Int J Cardiol 2013; 167: 2710–2718.

28. Malhotra R, Bakken K, D’Elia E, et al. Cardiopulmonary exercise testing in heart failure. JACC Heart Failure 2016; 4: 607–616.

29. Ouwerkerk W, Voors AA and Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429–366.

30. Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure. A systematic review and analysis. JACC Heart Fail 2014; 2: 440–446.

31. Levy WC; Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. JACC Heart Fail 2014; 2: 429–366.

32. Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.

33. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007; 115: 204–212.

34. Kirklin A, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. J Heart Lung Transplant 2017; 36: 1080–1086.

35. Alba AC, Rao V, Ivanov J, et al. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009; 28: 827–833.

36. Schaffer JM, Allen JG, Weiss ES, et al. Evaluation of risk indices in continuous-flow left ventricular assist device patients. Ann Thorac Surg 2009; 88: 1889–1896.
37. Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end stage heart failure. *J Card Fail* 2003; 9: 180–187.

38. Anker SD, Schroeder S, Atar D, et al. Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency. *Eur J Heart Fail* 2016; 18: 482–489.

39. Di Tanna GL, Wirtz H, Burrows KL, et al. Evaluating risk prediction models for adults with heart failure: A systematic literature review. *PLoS One* 2020; 15: e0224135.

40. Desai RJ, Wang SV, Vaduganathan M, et al. Comparison of machine learning methods with traditional models for use of administrative claims with electronic medical records to predict heart failure outcomes. *JAMA Netw Open* 2020; 3: e1918962.

41. O’Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction. The HF-ACTION predictive risk score model. *Circ Heart Fail* 2012; 5: 63–71.

42. O’Connor CM, Whellan DJ, Lee KL, et al.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009; 301: 1439–1450.

43. Chyu J, Fonarow GC, Tseng CH, et al. Four-variable risk model in men and women with heart failure, *Circ Heart Fail* 2014; 7: 88–95.

44. Aaronson KD, Schwartz JS, Chen T-M, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. *Circulation* 1997; 95: 2660–2667.

45. Goda A, Lund LH and Mancini DM. Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. *Am J Cardiol* 2010; 105: 1439–1444.

46. Levy WC, Aaronson KD, Dardas TF, et al. Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. *J Heart Lung Transplant* 2012; 31: 817–824.

47. Dardas T, Li Y, Reed SR, et al. Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure. *J Heart Lung Transplant* 2015; 34: 1017–1023.

48. Agostoni P, Paolillo S, Mapelli M, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: A long-term comparison. *Eur J Heart Fail* 2018; 20: 700–710.

49. Levy WC and Dardas TF. Comparison of cardiopulmonary-based risk models with a clinical heart failure risk model. *Eur J Heart Fail* 2018; 20: 711–714.

50. Freitas P, Aguiar C, Ferreira A, et al. Comparative analysis of four scores to stratify patients with heart failure and reduced ejection fraction. *Am J Cardiol* 2017; 120: 443–449.

51. Pocock SJ, Ariri CA, McMurray JJV, et al.; on behalf of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC). Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. *Eur Heart J* 2013; 34: 1404–1413.

52. Canepa M, Fonseca C, Chioncel O, et al. Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure long-Term registry. *JACC Heart Fail* 2018; 6: 452–462.

53. Kouwert IJM, Bakker EA, Cramer MJ, et al. Performance of MAGGIC and MECKI risk scores to predict mortality after cardiac rehabilitation among Dutch heart failure patients. *Eur J Prev Cardiol* Epub ahead of print 26 July 2019. DOI: 10.1177/2047487319865730.